Concepedia

Paul Fleming

PF

17

Publications

2.2K

Citations

15

H-Index

1991

Active since

Affiliations

Millennium Engineering and Integration (United States)(Current)

Blueprint Medicines (United States)

Takeda (United States)

Takeda (Japan)

University of Washington

Paul Fleming is an author at Millennium Engineering and Integration (United States) specializing in natural sciences, medicine, and biochemistry.

ORCID

Top concepts

Publications per year

1991–2024

17

Publications

17

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

Erik Kupperman, Edmund C. Lee, Yueying Cao et al. · Cancer Research · 2010 · 488 citations

, , +21

A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment

Marc L. Hyer, Michael A. Milhollen, Jeff Ciavarri et al. · Nature Medicine · 2018 · 414 citations

, , +8

Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers

Vivek Subbiah, Justin F. Gainor, Rami Rahal et al. · Cancer Discovery · 2018 · 386 citations

Parallel synthesis of 3-aminoimidazo[1,2-a]pyridines and pyrazines by a new three-component condensation

Christopher Blackburn, Bing Guan, Paul Fleming et al. · Tetrahedron Letters · 1998 · 361 citations

, , +6

Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit

Christopher Blackburn, Kenneth M. Gigstad, Paul Hales et al. · Biochemical Journal · 2010 · 144 citations · Full text

Rows per page

1–5 of 17